ALX Oncology to Host Virtual R&D Day on March 5, 2025
ALX Oncology (Nasdaq: ALXO) has announced a virtual Research and Development (R&D) Day scheduled for March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The event will provide comprehensive updates on the company's pipeline developments, with a particular focus on their lead investigational CD47-blocker evorpacept.
The virtual webcast will feature presentations from company leadership and external key opinion leaders, offering insights into clinical program progress along with business and financial updates. Interested participants can access the live webcast through the 'Investors' section of ALX Oncology's website under 'Events and Presentations,' with a replay available after the event.
ALX Oncology (Nasdaq: ALXO) ha annunciato una Giornata di Ricerca e Sviluppo (R&D) virtuale fissata per il 5 marzo 2025, alle 6:00 PT/9:00 ET. L'evento fornirà aggiornamenti completi sui progressi della pipeline dell'azienda, con particolare attenzione al loro principale inibitore sperimentale CD47 evorpacept.
Il webcast virtuale presenterà relazioni da parte della direzione dell'azienda e di esperti esterni, offrendo approfondimenti sui progressi dei programmi clinici insieme ad aggiornamenti aziendali e finanziari. I partecipanti interessati possono accedere al webcast dal vivo attraverso la sezione 'Investitori' del sito web di ALX Oncology sotto 'Eventi e Presentazioni', con una registrazione disponibile dopo l'evento.
ALX Oncology (Nasdaq: ALXO) ha anunciado un Día Virtual de Investigación y Desarrollo (I+D) programado para el 5 de marzo de 2025, a las 6:00 a.m. PT/9:00 a.m. ET. El evento proporcionará actualizaciones completas sobre los desarrollos en la cartera de la empresa, con un enfoque particular en su principal bloqueador experimental de CD47 evorpacept.
El webcast virtual contará con presentaciones de los líderes de la empresa y de líderes de opinión externos, ofreciendo perspectivas sobre el progreso de los programas clínicos junto con actualizaciones comerciales y financieras. Los participantes interesados pueden acceder al webcast en vivo a través de la sección 'Inversores' del sitio web de ALX Oncology bajo 'Eventos y Presentaciones', con una repetición disponible después del evento.
ALX Oncology (Nasdaq: ALXO)는 연구 및 개발(R&D) 데이를 2025년 3월 5일 오전 6시 PT/오전 9시 ET에 가상으로 개최한다고 발표했습니다. 이 행사에서는 회사의 파이프라인 개발에 대한 포괄적인 업데이트를 제공하며, 특히 주요 실험적 CD47 억제제인 evorpacept에 중점을 둘 것입니다.
가상 웹캐스트에서는 회사 리더십과 외부 주요 의견 리더의 발표가 포함되어 임상 프로그램 진행 상황과 비즈니스 및 재무 업데이트에 대한 통찰력을 제공합니다. 관심 있는 참가자는 ALX Oncology 웹사이트의 '투자자' 섹션에서 '이벤트 및 발표'를 통해 라이브 웹캐스트에 접속할 수 있으며, 이벤트 후에는 재생이 가능합니다.
ALX Oncology (Nasdaq: ALXO) a annoncé une Journée de Recherche et Développement (R&D) virtuelle prévue pour le 5 mars 2025 à 6h00 PT/9h00 ET. L'événement fournira des mises à jour complètes sur les développements du pipeline de l'entreprise, avec un accent particulier sur leur principal bloqueur expérimental de CD47 evorpacept.
Le webcast virtuel comprendra des présentations de la direction de l'entreprise et de leaders d'opinion externes, offrant des perspectives sur l'avancement des programmes cliniques ainsi que des mises à jour commerciales et financières. Les participants intéressés peuvent accéder au webcast en direct via la section 'Investisseurs' du site Web d'ALX Oncology sous 'Événements et Présentations', avec une rediffusion disponible après l'événement.
ALX Oncology (Nasdaq: ALXO) hat einen virtuellen Forschung und Entwicklungstag (R&D) angekündigt, der für den 5. März 2025 um 6:00 Uhr PT/9:00 Uhr ET geplant ist. Die Veranstaltung wird umfassende Updates zu den Entwicklungen in der Pipeline des Unternehmens bieten, mit besonderem Fokus auf ihren führenden experimentellen CD47-Blocker evorpacept.
Der virtuelle Webcast wird Präsentationen von der Unternehmensleitung und externen Meinungsführern umfassen und Einblicke in den Fortschritt der klinischen Programme sowie in geschäftliche und finanzielle Updates bieten. Interessierte Teilnehmer können über den Bereich 'Investoren' auf der Website von ALX Oncology unter 'Veranstaltungen und Präsentationen' auf den Live-Webcast zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updates
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company’s pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates.
R&D Day Webcast Information
The ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”
Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/yfucf8t5
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
FAQ
When is ALX Oncology (ALXO) hosting its R&D Day in 2025?
What will be discussed at ALXO's March 2025 R&D Day?
How can investors access ALXO's R&D Day presentation?
What is the main drug candidate being discussed at ALXO's R&D Day?
